KATIE BONAR: Open Payments
NPI 1083254320 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$265 in 15 payments from 7 companies in 2025. Trend: 2023 $374 · 2024 $573 · 2025 $265
Food & beverage: $265
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $104 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Novo Nordisk Inc | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Amgen Inc. | 1 | $16 |
Products named: VRAYLAR, BREZTRI, Ozempic, UBRELVY, GVOKE HYPOPEN, Korlym, TRELEGY ELLIPTA, OTEZLA.
Industry payments across AL — which companies pay providers there.
